Drug intelligence / Profile preview

allogeneic hematopoietic stem cell transplantation (University of Texas MD Anderson Cancer Center)

Development stage: Phase 3
Lead developer: University of Texas MD Anderson Cancer Center
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

Allogeneic hematopoietic stem cell transplantation (AHSCT) is a cellular therapy being evaluated by M.D. Anderson Cancer Center as an early salvage treatment for patients with primary induction failure (PIF) acute myeloid leukemia (AML). The procedure involves the infusion of donor-derived hematopoietic progenitor cells (typically CD34+ cells from bone marrow or peripheral blood) into a recipient following a conditioning regimen. In the specific protocol studied at M.D. Anderson, AHSCT follows a salvage chemotherapy regimen known as DCIA (decitabine, clofarabine, idarubicin, and cytarabine). The therapeutic effect is achieved through the reconstitution of the recipient's hematopoietic and immune systems and the induction of a graft-versus-leukemia (GVL) effect, where donor-derived immune cells recognize and eliminate residual leukemic cells.

Other names: stem cell-M.D. Anderson Cancer Center-acute myeloid leukemiaAHSCTallo-HSCTallogeneic stem cell infusionallogeneic hematopoietic progenitor cell infusion

Beyond the preview

Go deeper on allogeneic hematopoietic stem cell transplantation (University of Texas MD Anderson Cancer Center).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on allogeneic hematopoietic stem cell transplantation (University of Texas MD Anderson Cancer Center).

Explore the full profile